{"id":220810,"date":"2026-08-27T11:56:00","date_gmt":"2026-08-27T06:26:00","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=220810"},"modified":"2026-08-27T11:56:03","modified_gmt":"2026-08-27T06:26:03","slug":"diagnostics-stocks-below-fair-value","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/","title":{"rendered":"3 Undervalued Diagnostics Stocks Trading Below Fair Value"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Diagnostics sector PE near 67.8. Dr Lal PathLabs trades at 59.5x. Metropolis Healthcare at 58.3x. Thyrocare at 54.8x.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Three diagnostics stocks, Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies, are trading below the sector&#8217;s average price to earnings ratio of close to 67.8 times while all three post positive return on equity. Thyrocare Technologies carries the highest return on equity of the group, while Dr Lal PathLabs runs the largest and most established pathology lab network. This gap between valuation and profitability is why these diagnostics stocks stand out on a simple sector screen, though a formal buy rating needs deeper company specific research.<\/p>\n<\/div>\n<p>India&#8217;s diagnostics industry has grown on rising preventive healthcare awareness and expanding pathology lab networks, pushing valuations across the healthcare delivery space to a rich average price to earnings ratio. Not every stock in the space trades at the same multiple. A screen of listed diagnostics stocks against the sector&#8217;s average price to earnings ratio surfaces three names still priced below that benchmark.<\/p>\n<p>Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies all currently trade below the broader healthcare industry PE, despite posting positive return on equity. This piece breaks down why each stock screens as undervalued, what the underlying financials show, and the risks that come with owning diagnostic chain operators.<\/p>\n<p style=\"margin-top: 24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=undervalued_diagnostics_articles\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Why_These_Diagnostics_Stocks_Screen_as_Undervalued\" title=\"Why These Diagnostics Stocks Screen as Undervalued\">Why These Diagnostics Stocks Screen as Undervalued<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Dr_Lal_PathLabs_Largest_Network_Scale\" title=\"Dr Lal PathLabs: Largest Network Scale\">Dr Lal PathLabs: Largest Network Scale<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Metropolis_Healthcare_Mid_Sized_Pan_India_Presence\" title=\"Metropolis Healthcare: Mid Sized Pan India Presence\">Metropolis Healthcare: Mid Sized Pan India Presence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Thyrocare_Technologies_Highest_ROE_Widest_Discount\" title=\"Thyrocare Technologies: Highest ROE, Widest Discount\">Thyrocare Technologies: Highest ROE, Widest Discount<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Valuation_Snapshot_PE_PB_and_Dividend_Yield\" title=\"Valuation Snapshot: PE, PB and Dividend Yield\">Valuation Snapshot: PE, PB and Dividend Yield<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Risks_to_Consider_Before_Buying_These_Diagnostics_Stocks\" title=\"Risks to Consider Before Buying These Diagnostics Stocks\">Risks to Consider Before Buying These Diagnostics Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Test_Pricing_and_Competitive_Intensity\" title=\"Test Pricing and Competitive Intensity\">Test Pricing and Competitive Intensity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Franchise_and_Collection_Centre_Dependence\" title=\"Franchise and Collection Centre Dependence\">Franchise and Collection Centre Dependence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Regulatory_and_Accreditation_Risk\" title=\"Regulatory and Accreditation Risk\">Regulatory and Accreditation Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Seasonal_and_Wellness_Package_Demand_Variability\" title=\"Seasonal and Wellness Package Demand Variability\">Seasonal and Wellness Package Demand Variability<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#How_to_Track_These_Diagnostics_Stocks\" title=\"How to Track These Diagnostics Stocks\">How to Track These Diagnostics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#FAQs_on_Undervalued_Diagnostics_Stocks\" title=\"FAQs on Undervalued Diagnostics Stocks\">FAQs on Undervalued Diagnostics Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Which_diagnostics_stocks_are_trading_below_the_sector_average_PE\" title=\"Which diagnostics stocks are trading below the sector average PE?\">Which diagnostics stocks are trading below the sector average PE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Is_Thyrocare_Technologies_undervalued_compared_to_its_sector\" title=\"Is Thyrocare Technologies undervalued compared to its sector?\">Is Thyrocare Technologies undervalued compared to its sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Which_of_these_diagnostics_stocks_has_the_highest_return_on_equity\" title=\"Which of these diagnostics stocks has the highest return on equity?\">Which of these diagnostics stocks has the highest return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#What_is_the_market_capitalisation_of_Dr_Lal_PathLabs\" title=\"What is the market capitalisation of Dr Lal PathLabs?\">What is the market capitalisation of Dr Lal PathLabs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Which_of_these_diagnostics_stocks_trades_at_the_lowest_valuation\" title=\"Which of these diagnostics stocks trades at the lowest valuation?\">Which of these diagnostics stocks trades at the lowest valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#What_are_the_main_risks_in_undervalued_diagnostics_stocks\" title=\"What are the main risks in undervalued diagnostics stocks?\">What are the main risks in undervalued diagnostics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-stocks-below-fair-value\/#Is_a_low_PE_enough_reason_to_buy_a_diagnostics_stock\" title=\"Is a low PE enough reason to buy a diagnostics stock?\">Is a low PE enough reason to buy a diagnostics stock?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Why_These_Diagnostics_Stocks_Screen_as_Undervalued\"><\/span><strong>Why These Diagnostics Stocks Screen as Undervalued<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The healthcare delivery industry, which includes diagnostic chains, currently carries an average price to earnings ratio of close to 67.8 times trailing earnings. A stock trading meaningfully below that average, while still posting positive return on equity, is a reasonable starting point for a relative valuation screen.<\/p>\n<p>All three companies below clear that bar, with Thyrocare Technologies standing out for the strongest return on equity of the group, a combination not always available among diagnostics stocks priced at a discount to the sector multiple.<\/p>\n<p>The table below lists these three companies alongside their current price, valuation multiple and return ratios.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<thead>\n<tr>\n<th>Company<\/th>\n<th>NSE Ticker<\/th>\n<th>CMP (Rs)<\/th>\n<th>PE Ratio<\/th>\n<th>Sector PE<\/th>\n<th>ROE<\/th>\n<th>Market Cap (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>LALPATHLAB<\/td>\n<td>1,932.70<\/td>\n<td>59.50<\/td>\n<td>67.76<\/td>\n<td>20.13%<\/td>\n<td>32,510<\/td>\n<\/tr>\n<tr>\n<td>Metropolis Healthcare<\/td>\n<td>METROPOLIS<\/td>\n<td>576.05<\/td>\n<td>58.34<\/td>\n<td>67.76<\/td>\n<td>12.56%<\/td>\n<td>11,833<\/td>\n<\/tr>\n<tr>\n<td>Thyrocare Technologies<\/td>\n<td>THYROCARE<\/td>\n<td>582.50<\/td>\n<td>54.77<\/td>\n<td>67.76<\/td>\n<td>27.85%<\/td>\n<td>9,633<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Largest_Network_Scale\"><\/span><strong>Dr Lal PathLabs: Largest Network Scale<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Lal PathLabs operates one of India&#8217;s largest networks of pathology labs and collection centres across North and East India. The stock trades at a price to earnings ratio of 59.50, below the sector average of 67.76, at a current price of around Rs 1,933.<\/p>\n<p>Return on equity of 20.13 percent is supported by a low debt to equity ratio of 0.08. On an EPS of Rs 32.55 and book value of Rs 149.45, the price to book multiple works out to 12.96, alongside a dividend yield of 1.06 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Metropolis_Healthcare_Mid_Sized_Pan_India_Presence\"><\/span><strong>Metropolis Healthcare: Mid Sized Pan India Presence<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Metropolis Healthcare runs a network of pathology labs with a pan India presence and a focus on specialised and wellness testing. Its price to earnings ratio of 58.34 sits just below the sector average of 67.76, at a current share price of around Rs 576.<\/p>\n<p>Return on equity of 12.56 percent is the most modest of the three diagnostics stocks, and the debt to equity ratio of 0.15 remains low. On an EPS of Rs 9.78 and book value of Rs 72.44, the price to book multiple works out to 7.88.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Thyrocare_Technologies_Highest_ROE_Widest_Discount\"><\/span><strong>Thyrocare Technologies: Highest ROE, Widest Discount<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Thyrocare Technologies operates a centralised processing lab model for diagnostic testing, focused on preventive health checks and wellness packages. The stock trades at 54.77 times trailing earnings, the widest discount to the sector average of 67.76 among these three diagnostics stocks, at a current price of around Rs 583.<\/p>\n<p>Return on equity of 27.85 percent is the highest of the group by a wide margin, and the debt to equity ratio of 0.09 remains low. On an EPS of Rs 11.05 and book value of Rs 32.21, the price to book multiple of 18.79 is the richest among these three names, alongside a dividend yield of 2.31 percent.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_Snapshot_PE_PB_and_Dividend_Yield\"><\/span><strong>Valuation Snapshot: PE, PB and Dividend Yield<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the headline price to earnings ratio, book value multiples and dividend yield round out the valuation picture for these three companies. Thyrocare Technologies commands the richest price to book multiple, consistent with its markedly higher return on equity.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Price to Book<\/th>\n<th>Book Value (Rs)<\/th>\n<th>Dividend Yield<\/th>\n<th>Debt to Equity<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>12.96<\/td>\n<td>149.45<\/td>\n<td>1.06%<\/td>\n<td>0.08<\/td>\n<\/tr>\n<tr>\n<td>Metropolis Healthcare<\/td>\n<td>7.88<\/td>\n<td>72.44<\/td>\n<td>0.88%<\/td>\n<td>0.15<\/td>\n<\/tr>\n<tr>\n<td>Thyrocare Technologies<\/td>\n<td>18.79<\/td>\n<td>32.21<\/td>\n<td>2.31%<\/td>\n<td>0.09<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Thyrocare Technologies pays the highest dividend yield of the three despite its higher book value multiple, while Metropolis Healthcare trades at the most modest valuation of the group across both PE and PB metrics.<\/p>\n<p style=\"margin-top: 24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Check Live PE, PB and ROE Data on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Consider_Before_Buying_These_Diagnostics_Stocks\"><\/span><strong>Risks to Consider Before Buying These Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A discount to the sector average price to earnings ratio does not remove company specific risk for diagnostics stocks tied to test volumes and pricing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Test_Pricing_and_Competitive_Intensity\"><\/span><strong>Test Pricing and Competitive Intensity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intense competition among diagnostic chains and standalone labs can pressure test pricing, particularly for routine and commoditised tests with low differentiation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Franchise_and_Collection_Centre_Dependence\"><\/span><strong>Franchise and Collection Centre Dependence<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Much of the network expansion for these companies relies on franchise partners and collection centres, making quality control and brand consistency an ongoing operational challenge.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_and_Accreditation_Risk\"><\/span><strong>Regulatory and Accreditation Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Diagnostic labs operate under regulatory and quality accreditation requirements, and any lapses can affect reputation and patient trust across the network.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Seasonal_and_Wellness_Package_Demand_Variability\"><\/span><strong>Seasonal and Wellness Package Demand Variability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Demand for preventive health checks and wellness packages can vary seasonally and with broader consumer sentiment, adding variability to quarterly test volumes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Track_These_Diagnostics_Stocks\"><\/span><strong>How to Track These Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors evaluating these three names should track quarterly test volume growth, realisation per test, and how the sector average PE moves relative to each company&#8217;s own multiple over time, rather than relying on the valuation gap in isolation among diagnostics stocks. Comparing these numbers regularly is the most reliable way to judge whether the discount to fair value remains intact or has already closed.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies share prices live and set price alerts.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies are the three diagnostics stocks currently trading below the sector&#8217;s average price to earnings ratio of close to 67.8 times, while all three post positive return on equity. That combination makes them worth a closer look for investors who already want exposure to India&#8217;s diagnostic testing theme, though pricing competition and franchise dependence mean position sizing and diversification still matter when adding these names to a portfolio.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Undervalued_Diagnostics_Stocks\"><\/span><strong>FAQs on Undervalued Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_diagnostics_stocks_are_trading_below_the_sector_average_PE\"><\/span><strong>Which diagnostics stocks are trading below the sector average PE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies are currently trading below the healthcare sector&#8217;s average price to earnings ratio of close to 67.8 times, based on live NSE and BSE pricing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Thyrocare_Technologies_undervalued_compared_to_its_sector\"><\/span><strong>Is Thyrocare Technologies undervalued compared to its sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Thyrocare Technologies trades at a price to earnings ratio of 54.77, the widest discount to the sector average of 67.76 among these three names, while delivering a return on equity of 27.85 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_diagnostics_stocks_has_the_highest_return_on_equity\"><\/span><strong>Which of these diagnostics stocks has the highest return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Thyrocare Technologies has by far the highest return on equity of the three at 27.85 percent, ahead of Dr Lal PathLabs at 20.13 percent and Metropolis Healthcare at 12.56 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_capitalisation_of_Dr_Lal_PathLabs\"><\/span><strong>What is the market capitalisation of Dr Lal PathLabs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs has a market capitalisation of around Rs 32,510 crore, with a price to earnings ratio of 59.50 against the sector average of 67.76.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_diagnostics_stocks_trades_at_the_lowest_valuation\"><\/span><strong>Which of these diagnostics stocks trades at the lowest valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Metropolis Healthcare trades at the most modest valuation of the three, with a price to earnings ratio of 58.34 and a price to book multiple of 7.88, both lower than Dr Lal PathLabs and Thyrocare Technologies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_in_undervalued_diagnostics_stocks\"><\/span><strong>What are the main risks in undervalued diagnostics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks include competitive pressure on test pricing, dependence on franchise and collection centre partners, regulatory and accreditation requirements, and seasonal variability in wellness package demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_a_low_PE_enough_reason_to_buy_a_diagnostics_stock\"><\/span><strong>Is a low PE enough reason to buy a diagnostics stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A price to earnings ratio below the sector average is a useful starting screen for diagnostics stocks but not a standalone buy signal. Investors should also review test volume growth, network quality and pricing trends before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies trade below the healthcare sector&#8217;s average PE of near 67.8.<\/p>\n","protected":false},"author":35,"featured_media":220809,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-220810","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["220809"],"_edit_lock":["1787811966:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["83"],"rank_math_title":["Undervalued Diagnostics Stocks Trading Below Fair Value"],"rank_math_description":["These diagnostics stocks, Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies, trade below the sector average PE."],"rank_math_focus_keyword":["diagnostics stocks"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["40200"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/diagnostics-stocks-below-fair-value.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/220810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=220810"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/220810\/revisions"}],"predecessor-version":[{"id":220877,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/220810\/revisions\/220877"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/220809"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=220810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=220810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=220810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}